Akèy › Skizofreni › Maryland
Etid klinik pou Skizofreni nan Maryland
17 etid pou Skizofreni ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- The Johns Hopkins Hospital, Baltimore
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07101094Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0192, Gaithersburg
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 28, 2026 · NCT07686263NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Gaithersburg
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 25, 2026 · NCT07114874A Study of Brenipatide in Adult Participants With Schizophrenia
- CBH Health, Gaithersburg
Ap rekriteFaz 2
Laj 18 a 55 · Tout sèks · Mizajou Sep 22, 2026 · NCT07410507A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
- CBH Health LLC., dba CenExel Gaithersburg MD, Gaithersburg
Ap rekriteFaz 1
Laj 18 a 55 · Tout sèks · Mizajou Sep 17, 2026 · NCT07734493A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
- Cbh Health - Gaithersburg /ID# 272932, Gaithersburg
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Sep 15, 2026 · NCT0714591852-week Open Label Safety-Tolerability Study
- CenExel Gaithersburg, Gaithersburg
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 9, 2026 · NCT07369154A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Gaithersburg
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Sep 1, 2026 · NCT07459647A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Cenexel CBH, Gaithersburg
Ap rekriteFaz 2
Laj 18 a 55 · Tout sèks · Mizajou Jun 23, 2026 · NCT07191483Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
- University of Maryland School of Medicine, Baltimore
Ap rekriteFaz 4
Laj 18 a 65 · Tout sèks · Mizajou May 4, 2026 · NCT05208190Synbiotic Compound to Reduce Symptoms of Schizophrenia
- Sheppard Pratt Health System, Batlimore
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Apr 7, 2026 · NCT04226898NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Gaithersburg
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Mar 6, 2026 · NCT06963034White Matter Plasticity in Schizophrenia
- Maryland Psychiatric Research Center, Catonsville
- University of Maryland Baltimore - Maryland Psychiatric Research Center, Catonsville
Ap rekrite
Laj 15 a 45 · Tout sèks · Mizajou Feb 20, 2026 · NCT06641297TMS for Inhibition Enhancement in Schizophrenia
- Maryland Psychiatric Research Center, Catonsville
Ap rekrite
Laj 18 a 45 · Tout sèks · Mizajou Feb 13, 2026 · NCT06155682CBT-CP for Veterans With SMI
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Feb 9, 2026 · NCT06758414Study of ALTO-101 in Patients With Schizophrenia
- Site 5062, Gaithersburg
Ap rekriteFaz 2
Laj 21 a 55 · Tout sèks · Mizajou Dec 26, 2025 · NCT06502964Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Reviva site, Gaithersburg
Ap rekriteFaz 3Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Dec 19, 2024 · NCT05184335Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.